HC Wainwright & Co. Maintains Buy on Chimerix, Lowers Price Target to $11
HC Wainwright & Co. analyst Edward White maintains Chimerix (NASDAQ:CMRX) with a Buy and lowers the price target from $24 to $11.
Mid-Afternoon Market Update: Dow Jumps 300 Points; Crude Oil Rises Over 3%
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 300 points on Monday.
Mid-Day Market Update: Dow Edges Higher; Data Storage Shares Surge
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 20 points on Monday.
Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M
Emergent BioSolutions Inc (NYSE:EBS) has agreed to acquire Chimerix Inc’s (NASDAQ:CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for…
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell
• AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Looking Into Chimerix’s Return On Capital Employed
Benzinga Pro data, Chimerix (NASDAQ:CMRX) reported Q4 sales of $46.00 thousand. Earnings fell to a loss of $39.50 million, resulting in a 112.81% decrease from last quarter.